Read more

October 24, 2019
1 min read
Save

Lower eyelid retraction improved with dermal regeneration matrix template

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Cat Burkat

SAN FRANCISCO — A bilayer dermal regeneration matrix template improved lower eyelid retraction in patients undergoing repair, Cat Burkat, MD, said in a presentation at the American Society of Ophthalmic Plastic and Reconstructive Surgery meeting.

“Lower eyelid retraction may recur despite appropriate surgical techniques and lead to further fibrosis that limits repair,” Burkat told Healio/OSN. “The bilayer dermal regeneration template can be considered in primary complex or recurrent cases.”

Burkat described the procedure as a transconjunctival approach below the tarsus with the elliptical/crescent bilayer dermal regeneration matrix template sutured between the tarsus and the recessed inferior retractors.

“The meshed dermal layer of collagen and glycosaminoglycans forms a new biointegrated layer inferior to the tarsus to prevent recurrence, while the more rigid silicone layer vertically bolsters the eyelid against gravity until it is removed,” she said.

Of 16 patients who underwent eyelid retraction repair using the bilayer implant for either upper or lower eyelid surgery, preoperative symptoms resolved and retraction improved in 95.2% of those who underwent lower eyelid repair. Superior fornix depth improved in those who underwent upper eyelid retraction repair.

“The spacer is surprisingly well-tolerated despite its rigidity and has demonstrated excellent surgical results in our series,” Burkat said. – by Patricia Nale, ELS

 

Reference:

Burkat C. Silicone scaffold support using the bilayer dermal regeneration correction of complex or recurrent lower eyelid retraction. Presented at: American Society of Ophthalmic Plastic and Reconstructive Surgery meeting; Oct. 10-11, 2019; San Francisco.

 

Disclosure: Burkat reports she is a consultant to Horizon Therapeutics.